Key Highlights

  • Pacira BioSciences (NASDAQ:PCRX) rose 44.61% over one month in published market data as of October 28, 2026, after an all-cash offer on October 8, 2026 of USD 36.50 per share.
  • Viatris (NASDAQ:VTRS) plans to pay USD 36.50 per share, valuing the equity at about USD 1.65 billion against a pre-deal market value of about USD 1.45 billion, as reported.
  • The latest quote of USD 36.37 sits about 0.4% below the offer, simple arithmetic on two published numbers, which signals that investors expect the deal to complete.
  • Pacira's non-opioid pain products include EXPAREL, ZILRETTA and the iovera device, but closing timing and conditions were not stated in the report reviewed for Pacira BioSciences (NASDAQ:PCRX).

The Viatris Offer

On October 8, 2026 Viatris announced a plan to acquire Pacira BioSciences (NASDAQ:PCRX), a specialty pharmaceutical company focused on non-opioid pain management, for USD 36.50 per share in cash. The report reviewed puts the equity value at about USD 1.65 billion and describes a surge of over 44%. It does not state a premium figure, closing timing, financing or conditions. Jefferies moved to a Hold rating on October 8, as reported. EXPAREL is a long-acting local anesthetic used after surgery, ZILRETTA is an extended-release injection for osteoarthritis knee pain, and iovera uses cold to block pain signals, which explains the appeal of the portfolio to a buyer. Pacira had also drawn an analyst upgrade on October 7, when the shares climbed 4.7%, as reported.

Deal Arithmetic

Because the offer is in cash, the stock tracks USD 36.50. The reported equity value of about USD 1.65 billion is about 14% above the pre-deal market value of about USD 1.45 billion, simple arithmetic on two reported totals, so part of the 44.61% monthly gain may have come before the announcement. A quote of USD 36.37 leaves a spread of about 0.4% to the offer, so the market sees a high chance of closing. The stock reached a new 52-week high on October 14, as reported, and its weekly move of 0.03% shows trading has settled around the offer price. Cash acquisitions of this kind can carry a termination fee, though none was reported, and shareholder and regulatory approvals typically take several months.

Risks and Next Steps

Risks include regulatory review, financing, shareholder approval and any change in terms, none of which was detailed in the report reviewed. If the deal failed, the stock could fall toward its pre-offer level. Upside above USD 36.50 would need a rival offer, and none is reported. A senior vice president sale of USD 217,920 of stock was reported on October 9. Pacira BioSciences (NASDAQ:PCRX) investors should watch the merger agreement filing for conditions, the shareholder vote date and any regulatory notice. A reported insider sale does not change the offer. Antitrust or regulatory review and the vote of Pacira holders are the usual gates for a cash acquisition of this size.

Where Things Stand

Pacira BioSciences (NASDAQ:PCRX) rose 44.61% because Viatris offered USD 36.50 per share in cash on October 8, 2026, and the stock now trades about 0.4% below the offer. This is a takeover move, so further upside needs a rival bid, and the main uncertainty is completion, since conditions and timing were not stated in the material reviewed. The next catalysts are the merger agreement filing and any shareholder or regulatory milestones.